Page 2 - Lumen Bioscience News Today

Mice vaccinated with spirulina expressing a malaria parasite protein were protected from infection, setting the stage for future clinical trials.

/PRNewswire/ -- DelveInsights Clostridium difficile Infection Market Insights report includes a comprehensive understanding of current treatment practices,...

The Clostridium difficile infection market is anticipated to surge owing to the launch of emerging therapies. The potential emerging treatment expected to launch in the forecast period includes

/PRNewswire/ -- DelveInsights Abdominal Aortic Aneurysm Market Insights report includes a comprehensive understanding of current treatment practices,...

The Abdominal Aortic Aneurysm market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast

/PRNewswire/ -- Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced clinical...

In a new paper, Lumen Bioscience detailed how spirulina can be genetically engineered for to rapidly produce large quantities of biologic drugs.

/PRNewswire/ -- A common food source has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs...

/PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...

/PRNewswire/ -- NEUVOGEN, an immunoncology company, is pleased to announce the appointment of George Montgomery as Chief Financial Officer. He will oversee...